Crossmark

Exclusion of electrical and mechanical function of the left atrial appendage in patients with persistent atrial fibrillation: differences in efficacy and safety between endocardial ablation vs epicardial LARIAT ligation (the EXCLUDE LAA study)

Crossref DOI link: https://doi.org/10.1007/s10840-019-00657-1

Published Online: 2019-12-20

Published Print: 2020-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Parikh, Valay

Rasekh, Abdi

Mohanty, Sanghamitra

Yarlagadda, Bharath

Atkins, Donita

Bommana, Sudha

Turagam, Mohit

Jeffery, Courtney

Carroll, Heidi

Nydegger, Cheri

Jaeger, Misty

Dar, Tawseef

Cheng, Jie

Gopinnathanair, Rakesh

Dibiase, Luigi

Lee, Randal

Horton, Rodney

Natale, Andrea

Lakkireddy, Dhanunjaya
License Information

Text and Data Mining valid from 2019-12-20

Version of Record valid from 2019-12-20
More Information

Article History

Received: 12 July 2019

Accepted: 29 October 2019

First Online: 20 December 2019

Compliance with ethical standards

:

: V. Parikh, S. Mohanty, B. Yarlagadda, D. Atkins, S. Bommana, M. Turagam, C. Jeffery, H. Carroll, C. Nydegger, M. Jaeger, T. Dar, J. Cheng, R. Gopinnathanair: None. A. Rasekh: Research support as a participant in the aMAZE trial. L. Di Biase: Consultant: Stereotaxis, Biosense Webster, St. Jude Medical; Speaker: Biotronik, Medtronic, Boston Scientific, Janssen, Pfizer, Epi EP. R. Lee: Equity holder in SentreHeart. R. Horton: None relevant to the study. A. Natale: Consultant: Stereotaxis, Biosense Webster, St. Jude Medical; Speaker: Biotronik, Medtronic, Boston Scientific, Janssen, Pfizer, Epi EP.D. Lakkireddy: Consultant: Atricure, St. Jude Medical, Northeast Medical, Abbott Vascular, Biosense Webster, AltaThera; Speaker: Biotronik, Medtronic, Boston Scientific, Janssen, Pfizer; Principal Investigator for aMAZE trial.

Document is current

Any future updates will be listed below